<DOC>
	<DOCNO>NCT01494688</DOCNO>
	<brief_summary>This open-label , multicenter , dose-escalation study ass safety , tolerability , pharmacokinetics pharmacodynamics RO5509554 participant advance solid tumor amenable standard treatment . In Part I ( Dose Escalation ) , multiple ascend dos RO5509554 administer monotherapy participant solid tumor . Participants locally advance and/or metastatic ovarian ( include fallopian tube ) breast carcinoma receive multiple ascending dos RO5509554 combination paclitaxel . In Part II ( Expansion Cohort ) , RO5509554 administer monotherapy participant locally advance and/or metastatic Pigmented Villonodular Synovitis ( PVNS ) /Tenosynovial Giant Cell Tumor ( TGCT ) , soft tissue sarcoma malignant mesothelioma , ovarian ( include fallopian tube ) , endometrial breast cancer pancreatic cancer . Participants Human Epidermal Growth Factor Receptor 2 ( HER2 ) /neu negative breast cancer receive RO5509554 combination paclitaxel . Anticipated time study treatment disease progression , unacceptable toxicity , death participant refusal , whichever occur first .</brief_summary>
	<brief_title>A Study RO5509554 Monotherapy Combination With Paclitaxel Participants With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Histologically confirm advanced and/or metastatic solid tumor amenable standard therapy , exception define exclusion criterion Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Measurable disease accord RECIST criterion version 1.1 Adequate bone marrow , cardiac , liver renal function Participants histologically proven Hepatocellular Carcinoma ( HC ) , Non Small Cell Lung Cancer ( NSCLC ) , Small Cell Lung Cancer ( SCLC ) , gastric cancer , malignant melanoma , nonmetastatic locally control PVNS/TGCT Participants know autoimmune disease Known suspect central nervous system ( CNS ) metastases include leptomeningeal metastasis ; participant radiologically stable , asymptomatic previously irradiate lesion eligible provide participant great equal ( &gt; /= ) 4 week beyond complete cranial irradiation &gt; /= 3 week corticosteroid therapy Significant , uncontrolled concomitant disease , include significant cardiovascular pulmonary disease Prior chemotherapy , radiotherapy ( short cycle palliative radiotherapy bone pain ) , investigational agent immunotherapy within 28 day first receipt study drug Prior corticosteroid anticancer therapy within minimum 14 day first receipt study drug Poorly control type 1 type 2 diabetes mellitus Prior toxicity chemotherapy radiotherapy regress Grade less equal ( &lt; /= ) 1 severity National Cancer InstituteCommon Terminology Criteria Adverse Events ( NCICTCAE ) version 4.03 late version Known Human Immunodeficiency Virus ( HIV ) , Hepatitis B Virus ( HBV ) Hepatitis C Virus ( HCV ) infection Pulmonary embolism thromboembolic event within 6 month prior study entry History hematological malignancy within last 5 year prior study entry Participant require high dose corticosteroid treatment ( i.e . great ( &gt; ) 20 mg dexamethasone day equivalent &gt; 7 consecutive day ) Any surgical procedure , include require baseline tumor biopsy , within less 14 day first receipt study drug . Major surgery within 28 day first receipt study drug Pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>